The US Food and Drug Administration (FDA) approved Eli Lilly’s Kisunla (donanemab-azbt), once-monthly injection for IV infusion), Alzheimer's treatment . 3 July 2024
Approximately 36% of the pharmaceutical manufacturing units inspected recently by the Indian drug regulator were shut down due to non-compliance with quality standards. 4 July 2024
New Jersey, USA-based biopharma firm Insmed (Nasdaq: INSM) has revealed additional positive outcomes from its Phase III ASPEN study of brensocatib. 4 July 2024
The global recombinant proteins market is projected to grow from $132 billion in 2023 to $203 billion by 2029, according to a recent BCC Research study. 4 July 2024
US biotech Moderna has received a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. 4 July 2024
British drugmaker GSK (LSE: GSK) and Germany's CureVac (Nasdaq: CVAC) have announced a restructuring of their collaboration into a new licensing agreement. 4 July 2024
A survey of British voters ahead of Thursday’s general election has revealed just how much importance they attach to the issue of access to medicines. 3 July 2024
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
LenioBio, a German biotech company focused on cell-free protein production, and UK-based enzymatic DNA production Touchlight have announced a supply agreement. 3 July 2024
The European Medicines Agency (EMA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). 3 July 2024
Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
An ophthalmic gene therapy company aiming to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.